Vivani Medical presents development plans for once- or twice-yearly semaglutide implant
VANI•Vivani Medical expects top-line results from its NPM-139 SLIM-1 Phase 1 trial in November 2026 and projects starting a Phase 2 dose-ranging study in 2027. The implant targets once- or twice-yearly dosing, and the company expects its cash runway to extend into mid-2027.
1. Trial and development plans
Vivani Medical said all patients in its SLIM-1 Phase 1 trial of semaglutide implant NPM-139 were dosed in August 2026, with top-line results expected in November 2026. The company projects starting a Phase 2 dose-ranging study in 2027; Novo Nordisk's evaluation of NPM-139 remains ongoing. The implant is being developed for once- or twice-yearly dosing for chronic weight management in obese or overweight patients, and Vivani expects its cash runway to fund its current operating plan, including key milestones, into mid-2027.
